Logo image of RAPP

RAPPORT THERAPEUTICS INC (RAPP) Stock Fundamental Analysis

NASDAQ:RAPP - Nasdaq - US75383L1026 - Currency: USD

10.18  +0.19 (+1.9%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RAPP. RAPP was compared to 192 industry peers in the Pharmaceuticals industry. While RAPP has a great health rating, there are worries on its profitability. RAPP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RAPP has reported negative net income.
RAPP Yearly Net Income VS EBIT VS OCF VS FCFRAPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of RAPP (-28.12%) is comparable to the rest of the industry.
With a decent Return On Equity value of -28.82%, RAPP is doing good in the industry, outperforming 68.23% of the companies in the same industry.
Industry RankSector Rank
ROA -28.12%
ROE -28.82%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RAPP Yearly ROA, ROE, ROICRAPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RAPP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPP Yearly Profit, Operating, Gross MarginsRAPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for RAPP remains at a similar level compared to 1 year ago.
The debt/assets ratio for RAPP has been reduced compared to a year ago.
RAPP Yearly Shares OutstandingRAPP Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M
RAPP Yearly Total Debt VS Total AssetsRAPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 27.07 indicates that RAPP is not in any danger for bankruptcy at the moment.
RAPP's Altman-Z score of 27.07 is amongst the best of the industry. RAPP outperforms 94.27% of its industry peers.
RAPP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.07
ROIC/WACCN/A
WACCN/A
RAPP Yearly LT Debt VS Equity VS FCFRAPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 50M 100M

2.3 Liquidity

RAPP has a Current Ratio of 45.91. This indicates that RAPP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 45.91, RAPP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
RAPP has a Quick Ratio of 45.91. This indicates that RAPP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 45.91, RAPP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 45.91
Quick Ratio 45.91
RAPP Yearly Current Assets VS Current LiabilitesRAPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for RAPP have decreased strongly by -226.57% in the last year.
EPS 1Y (TTM)-226.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RAPP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -60.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-283.81%
EPS Next 2Y-84.25%
EPS Next 3Y-60.41%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPP Yearly Revenue VS EstimatesRAPP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026
RAPP Yearly EPS VS EstimatesRAPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RAPP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RAPP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPP Price Earnings VS Forward Price EarningsRAPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPP Per share dataRAPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

RAPP's earnings are expected to decrease with -60.41% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.25%
EPS Next 3Y-60.41%

More info and screens

0

5. Dividend

5.1 Amount

RAPP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPPORT THERAPEUTICS INC

NASDAQ:RAPP (3/5/2025, 2:16:01 PM)

10.18

+0.19 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners119.17%
Inst Owner Change28.56%
Ins Owners6.54%
Ins Owner Change0%
Market Cap372.38M
Analysts86
Price Target38.08 (274.07%)
Short Float %4.97%
Short Ratio12.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-65.95%
Min EPS beat(2)-146.79%
Max EPS beat(2)14.9%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-2.62
EYN/A
EPS(NY)-3.34
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS8.83
TBVpS8.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.12%
ROE -28.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 45.91
Quick Ratio 45.91
Altman-Z 27.07
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-226.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-283.81%
EPS Next 2Y-84.25%
EPS Next 3Y-60.41%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-248.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-143.52%
EBIT Next 3Y-72.62%
EBIT Next 5YN/A
FCF growth 1Y-717.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-738.4%
OCF growth 3YN/A
OCF growth 5YN/A